Aura Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2019--
Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 2:00 p.m. Eastern Time in New York, NY.
About Aura Biosciences
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005088/en/
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY OPTICAL
SOURCE: Aura Biosciences
Copyright Business Wire 2019.
PUB: 05/28/2019 07:00 AM/DISC: 05/28/2019 07:01 AM